← Back to Clinical Trials
Recruiting NCT04142606

NCT04142606 LUMIERE on the FETUS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04142606
Status Recruiting
Phase
Sponsor Assistance Publique - Hôpitaux de Paris
Condition Pregnancy
Study Type OBSERVATIONAL
Enrollment 1,500 participants
Start Date 2019-12-06
Primary Completion 2026-12

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
fetal MRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,500 participants in total. It began in 2019-12-06 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Congenital anomalies are a major public health problem. They affect 2-3% of births, around 20,000 new cases per year in France, of which 15% are cared for in Ile de France. These congenital anomalies are a major cause of morbidity, infant mortality and disability. They are also a major cause of death during the infant period (22% of deaths during the first year of life: source CépiDC Inserm 2010). The detection, accurate diagnosis and accurate prognosis, particularly functional, of these congenital anomalies are still difficult in the current monitoring of pregnancy, which is based primarily on ultrasound. The use and development of modern imaging techniques is now essential to enable doctors to better see and better examine the fetus. Alongside ultrasound, Magnetic Resonance Imaging (MRI) is a technique that has undergone significant development in recent years. MRI must allow the effective anatomical and functional evaluation of the main fetal organs and could in particular be interesting in several situations in which it has not yet been sufficiently evaluated and is not yet performed in clinical routine.

Eligibility Criteria

Inclusion Criteria: * patient ≥ 18 years * Single or twin pregnancy * gestational age≥ 16 WG and ≤ 36 WG based on cranio-caudal length (LCC) dating * Collection of the patient's consent Exclusion Criteria: contraindication to MRI * multiple pregnancies \> 2 * subsequent follow-up impossible * maternal condition contraindicates continuation of pregnancy * patient having to have an MRI examination as part of the normal clinical follow-up of her pregnancy (identified or strongly suspected echocardiographic abnormality on ultrasound, diaphragmatic dome hernia, CMV fetal infection, antecedent brain abnormality in siblings, STT operated)

Contact & Investigator

Central Contact

David Grevent, MD PHD

✉ david.grevent@gmail.com

📞 + 33144841734

Principal Investigator

Laurent Salomon, MD, PhD

PRINCIPAL INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Frequently Asked Questions

Who can join the NCT04142606 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04142606 currently recruiting?

Yes, NCT04142606 is actively recruiting participants. Contact the research team at david.grevent@gmail.com for enrollment information.

Where is the NCT04142606 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT04142606 clinical trial?

NCT04142606 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Laurent Salomon, MD, PhD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 1,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology